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Abstract Rituximab is a chimeric human-mouse anti-
CD20 monoclonal antibody, which is used in the treatment
of both B-cell lymphomas and rheumatic diseases. We
describe a case of a previously healthy 57-year-old man
developing arthritis while being treated with rituximab-
CHOP chemotherapy (R-CHOP) for a non-Hodgkin lym-
phoma. The remittant arthritis developed at successively
shorter time-intervals after R-CHOP administration and
only improved after rituximab was removed from the
chemotherapy schedule, suggesting a rituximab-related
phenomenon, as extensive diagnostic testing ruled out any
other diagnosis.
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Introduction
Rituximab is increasingly used in the treatment of both B-
cell lymphomas as well as rheumatic diseases. Several side-
effects of rituximab are known, but until now only two
reports described the development of arthritis after rituximab
therapy [1, 2]. Here we describe yet another case.
Case
A 57-year-old man was referred to the out-patient clinic of
rheumatology because of arthritis of the right knee and left
wrist.
The patient had been in perfect health until he noticed a
swelling of 2.5 cm under his right jaw. He was referred to a
specialized oncology center where he was diagnosed with
an aggressive follicular B-cell non-Hodgkin lymphoma
(NHL) stage IVA with involvement of submandibular and
mesenteric lymph nodes and bone marrow. Treatment was
instituted with R-CHOP chemotherapy, which consists of
cyclophosphamide, doxorubicin, vincristine, prednisone,
and rituximab, given at a 3-week interval. During this
treatment, granisetron (Kytril®) was given and occasionally
magnesiumoxide and paracetamol. Because this patient
suffered from a low tumor burden, no tumor lysis
profylaxis, i.e., allopurinol was prescribed.
Two and a half weeks after the first course of R-CHOP,
the patient developed arthritis of his right knee and left
wrist without morning stiffness or involvement of the small
hand joints. He had no history of arthralgia, joint swelling,
preceding trauma, fever, or infection nor did he have a
history of inflammation of the eyes, Raynaud phenomenon,
photosensitivity, sicca-syndrome, or inflammatory back
pain. The further medical history disclosed several tick
bites the year before, with a skin reaction. He rarely used
alcohol (maximum of two glasses a day). Family history
revealed no rheumatic diseases.
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painful right knee and left wrist. The other joints were not
afflicted.
Laboratory testing before the start of chemotherapy
showed no abnormalities besides a erythrocyte sedimenta-
tion rate (ESR) of 21 mm/h. At the time of presentation
with arthritis, there was ESR of 41 mm/h, C-reactive
protein 256 mg/l, leucocytes 11.1×10
9/l, a normal liver and
kidney function, and an IgM-rheumatoid factor (RF) 7 IE/ml,
anti-cyclic citrulline peptide (a-CCP) <1 AU/ml, anti-nuclear
factor(ANF) negative,and urate of0.25mmol/l. A diagnostic
puncture of synovial fluid from the right knee was performed,
which revealed an inflammatory arthropathy (cell count
5,300/mm
3, 14% lymphocytes, 8% mononuclear cells, and
78% granulocytes) with no signs of malignant cells or
crystals. Microbiological testing (Gram-stain, Ziehl–Neelsen,
and culture) of the synovial fluid showed no microorgan-
isms. X-rays of both knee and wrist did not show bone
involvement or chondrocalcinosis. The patient was treated
with naproxen (500 mg, twice daily), with which both pain
and swelling of the joints were reduced but not completely
resolved.
Four days after the second course of R-CHOP, the pain
and swelling returned in all its severity and spontaneously
regressed after 1 week.
Shortly after the third course of R-CHOP, the patient
experienced the same painful joint swellings, now also
involving the left knee. This was in spite of intra-articular
kenacort injections and prednisone maintenance therapy
(10 mg daily), which was started between the courses of
chemotherapy. Repeated pathological and microbiological
testing of synovial fluid showed no new results.
After these three courses of R-CHOP, the effect on the
NHL was evaluated and disclosed that the intra-abdominal
NHL-mass was somewhat reduced, and the remnant of the
submandibular lymph node had disappeared.
Since the causal relationship between the (activity of)
arthritis and the courses of R-CHOP and rituximab being
the only component of R-CHOP of which the development
of arthritis is described after the administration of this drug
[1, 2], the decision was made to give the fourth and fifth
course of chemotherapy without rituximab. This time there
was no increase in pain or swelling of the joints.
Well over a year after the first R-CHOP chemotherapy,
the patient is fully recovered. Evaluation of his NHL shows
a near complete remission, and no further treatment was
indicated. The arthritis has fully resolved.
Discussion
Arthritis developing during the course of R-CHOP chemo-
therapy is very unusual. The arthritis developed after succes-
sively shorter time-intervals after the R-CHOP administration
while no arthritis occurred when CHOP was given without
rituximab. This suggests a probably rituximab related, im-
mune-mediated phenomenon. We were not able to detect
antibodies against rituximab or immune complexes that might
strengthen this diagnosis. However, we did have strong
arguments against the other differential diagnoses.
The pattern of arthritis in this patient is unusual for a
rheumatoid arthritis; moreover, both IgM-RF and a-CCP
were negative, while X-rays made of the afflicted joints
disclosed no erosions.
Spondylarthropathy very rarely develops after the age of
45 years. Moreover, inflammatory back pain was absent,
and positive arguments for an infection causing reactive
arthritis were lacking.
Other autoimmune diseases like systemic lupus erythe-
matosus (SLE) or Sjögren’s syndrome were also very
unlikely looking at the clinical presentation, the absence
of characteristic signs and symptoms, and the absence of
the specific autoantibodies.
A crystalarthropathy is a more likely candidate, as
treatment of NHL can cause tumor lysis syndrome, which
can give rise to gout. However, serum values of urine acid
were repeatedly very low, and there where no other signs of
tumor lysis syndrome. Moreover, repeated samples of
synovial fluid failed to show any crystals, kidney function
was normal; the patient barely used alcohol and did not use
diuretics.
The X-rays of both the right knee and left wrist did not
show signs of chondrocalcinosis.
Latent infections provoked by the administration of R-
CHOP were considered. However, repeated cultures, Gram-
stain, and Ziehl–Neelsen of synovial fluid did not disclose
any bacteria or yeasts. Serologic testing for Borrelia
Burgdorferi, Lues, Chlamydia trachomatis, Parvovirus
B19 and PCR on Mycobacteria tuberculosis and Chlamydia
trachomatis (both performed in the synovial fluid) proved
to be negative.
A wide spectrum of autoimmune manifestations, among
others arthritis, is described in NHL [3]. However, arthritis
is unlikely in this patient as autoimmune manifestation, as it
developed during R-CHOP and the NHL responded well to
this chemotherapy.
Furthermore intra-articular localization of NHL was
considered. However, both primary and secondary intra-
articular localization of NHL is very rare [4], and the fact
that more than one joint is afflicted in this patient makes it
even more unlikely. Moreover, magnetic resonance imaging
(MRI) of both knees did not show tumor mass, and
repeated punctures of synovial fluid of both knees did not
show any malignant cells. On top of this, a computed
tomography (CT) scan of the abdomen revealed regression
of the mesenteric NHL-tumor mass after chemotherapy,
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articular localization of NHL, one would expect relapse of
joint involvement in the course of chemotherapy instead of
progression.
An arthroscopy was considered but not performed
because of the risks of infection in this immunocompro-
mised patient, and the low expectancy of achieving the
diagnosis by performing the arthroscopy as the presence of
NHL intra-articular was considered to be very unlikely.
Because our patient received high dosages of prednisone,
the diagnosis of avascular bone necrosis was considered but
ruled out by a MRI of both knees. None of the other
medications our patient used are known to give arthritis.
Ruling out the above-mentioned diagnoses and taking
into account the relationship in time between the develop-
ment of arthritis and the gifts of R-CHOP, one or more of
the components of R-CHOP seem to be the most likely
cause of the arthritis in our patient. Of all of the components
of R-CHOP, only rituximab is known to be able to give
arthritis [1, 2].
Pijpe et al. described the development of arthritis in three
patients who received rituximab for primary Sjögren’s
syndrome. All of these patients had developed human
antichimeric antibodies (HACAs), which suggests an
immune-mediated mechanism. Only one other patient
tested positive for HACAs but was asymptomatic. The
significance of HACAs being present is actually not quite
sure as other studies show HACAs being present without
specific clinical manifestations [5, 6] or show HACAs
being present but later becoming undetectable [6].
Repeated blood tests of our patient did not show any
HACAs. The precise mechanism of action in the develop-
ment of arthritis in our patient is still unknown.
In conclusion, we describe a patient developing severe
oligo-arthritis at successively shorter time-intervals after
receiving CHOP-rituximab for a NHL. The arthritis is
probably caused by an immune-mediated reaction to
rituximab. As it is to be expected that rituximab will be
used more frequently in future to treat both NHL as
rheumatological diseases, we think it is important for
physicians to be aware that rituximab may cause severe
(oligo-)arthritis as a side effect.
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